AssetMark Inc’s Silence Therapeutics SLN Stock Holding History

AssetMark Inc’s Portfolio SLN Stock Details SLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.29K	Buy	+118	New	+$1.44K	﹤0.01%	3176

Other funds holding SLN

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

AssetMark Inc's SLN Position: Q3 2026 in Review

AssetMark Inc opened a new position in Silence Therapeutics (SLN) in Q3 2026: 118 shares worth $1.29K. The stake represents ﹤0.01% of the portfolio and ranks #3176 among its holdings.

6 funds tracked by Wall St. Rank hold SLN as of Q3 2026.

AssetMark Inc held 118 shares of Silence Therapeutics worth $1.29K as of Q3 2026.
Silence Therapeutics was a new AssetMark Inc position in Q3 2026.
Silence Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #3176 holding.
6 funds tracked by Wall St. Rank held Silence Therapeutics as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.